A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs TPI 287 (Primary)
- Indications Brain metastases
- Focus Adverse reactions
- 28 Sep 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 28 Sep 2017 Status changed from recruiting to suspended.
- 20 Nov 2015 Results published in a Cortice Biosciences media release.